LCM
INDP icon

Laurion Capital Management’s Indaptus Therapeutics INDP Stock Holding History

Laurion Capital Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42
Closed -$532K – 1240
2018
Q3 		$532K Buy
+42
New +$399K 0.01% 815

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return

Laurion Capital Management's INDP Position: Q4 2018 in Review

Laurion Capital Management sold out of Indaptus Therapeutics (INDP) in Q4 2018, closing a stake of 42 shares — an estimated $532K sold.

Laurion Capital Management first reported a position in INDP in Q3 2018 and held it in 1 quarter. The position peaked at $532K in Q3 2018. 30 funds tracked by Wall St. Rank hold INDP as of Q4 2018.

  • Laurion Capital Management reported no remaining Indaptus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Laurion Capital Management sold 42 Indaptus Therapeutics shares in Q4 2018, an estimated $532K.
  • Laurion Capital Management first reported a position in Indaptus Therapeutics in Q3 2018 and held it in 1 quarter.
  • Laurion Capital Management's Indaptus Therapeutics position peaked at $532K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2018.

Based on Laurion Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.